Multiple Myeloma Clinical Trial

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Summary

The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy and autologous stem cell transplant (ASCT).

View Full Description

Full Description

The study consists of 3 phases: Screening Phase (within 21 days prior to randomization), Treatment Phase (Cycle 1 Day 1 to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, withdrawal of consent, or the study ends, whichever occurs first). Treatment phase will include 2 treatments (Treatment A: participants will receive Velcade MelphalanPrednisone (VMP) alone and Treatment B: participants will receive daratumumab in combination with VMP).Two interim analyses are planned. The first will be to evaluate safety after a total of approximately 100 participants have been treated for at least 2 cycles or discontinued the study treatment. The second will be to evaluate cumulative interim safety and efficacy data, and will be performed when approximately 216 PFS events have been accumulated. The final OS analysis will occur when approximately 382 deaths have occurred. Efficacy will be primarily measured by comparison of PFS between the two treatment arms. Participants' safety will be monitored throughout the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant must have documented multiple myeloma satisfying the calcium elevation, renal insufficiency, anemia, and bone abnormalities (CRAB) diagnostic criteria, monoclonal plasma cells in the bone marrow greater than or equal to 10 percent (%) or presence of a biopsy proven plasmacytoma, and measurable secretory disease, as assessed by the central laboratory, and defined in protocol
Participants who are newly diagnosed and not considered candidate for high-dose chemotherapy with stem cell transplantation (SCT) due to: being age >=65 years, or in participants <65 years: presence of important comorbid conditions likely to have a negative impact on tolerability high dose chemotherapy with stem cell transplantation
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
Meet the clinical laboratory criteria as specified in the protocol
A woman of childbearing potential must have a negative serum pregnancy test at screening within 14 days prior to randomization
Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin prior to dosing. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy

Exclusion Criteria:

Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma
Participant has a diagnosis of Waldenstrom's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of corticosteroids before treatment
Participant has peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute common terminology criteria for adverse events (NCI CTCAE) Version 4
Participant has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years)
Participant has had radiation therapy within 14 days of randomization
Participant has had plasmapheresis within 28 days of randomization
Participant has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] <50% of predicted normal), known moderate or severe persistent asthma within the last 2 years or currently has uncontrolled asthma of any classification (controlled intermittent asthma or controlled mild persistent asthma is allowed)
Participants with known or suspected COPD must have a FEV1 test during screening
Participant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis C
Participant has any concurrent medical or psychiatric condition or disease (example active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

706

Study ID:

NCT02195479

Recruitment Status:

Active, not recruiting

Sponsor:

Janssen Research & Development, LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


California City California, , United States

Corona California, , United States

Fountain Valley California, , United States

Los Angeles California, , United States

Hialeah Florida, , United States

Orange Park Florida, , United States

Chicago Illinois, , United States

Springfield Missouri, , United States

Cleveland Ohio, , United States

Fredericksburg Virginia, , United States

Buenos Aires , , Argentina

Ciudad Autonoma Buenos Aires , , Argentina

Córdoba , , Argentina

Santa Fe , , Argentina

Adelaide , , Australia

Bendigo , , Australia

Camperdown N/a , , Australia

Geelong , , Australia

Gosford , , Australia

Greenslopes , , Australia

Hobart , , Australia

North Adelaide , , Australia

Parkville , , Australia

Antwerpen , , Belgium

Antwerp , , Belgium

Brussel , , Belgium

Charleroi , , Belgium

Gent , , Belgium

Kortrijk , , Belgium

Roeselare , , Belgium

Turnhout , , Belgium

Yvoir , , Belgium

Barretos , , Brazil

Cuiaba - Mount , , Brazil

Fortaleza , , Brazil

Goiânia , , Brazil

Natal , , Brazil

Porto Alegre , , Brazil

Ribeirao Preto , , Brazil

Rio de Janeiro , , Brazil

Sao Paulo , , Brazil

São Paulo , , Brazil

Pleven , , Bulgaria

Plovdiv , , Bulgaria

Sofia , , Bulgaria

Varna , , Bulgaria

Vratsa , , Bulgaria

Zadar , , Croatia

Zagreb , , Croatia

Brno , , Czechia

Hradec Kralove , , Czechia

Olomouc , , Czechia

Ostrava-Poruba , , Czechia

Praha 10 , , Czechia

Praha 2 , , Czechia

Tbilisi , , Georgia

Berlin , , Germany

Dortmund , , Germany

Karlsruhe , , Germany

Potsdam , , Germany

Saarbrücken , , Germany

Stuttgart , , Germany

Würzburg , , Germany

Athens Attica , , Greece

Athens , , Greece

Patra , , Greece

Thessaloniki , , Greece

Budapest , , Hungary

Debrecen , , Hungary

Kaposvar , , Hungary

Pecs N/a , , Hungary

Chiba , , Japan

Hitachi , , Japan

Kanazawa , , Japan

Kawasaki , , Japan

Kobe , , Japan

Kurume , , Japan

Matsuyama , , Japan

Nagoya , , Japan

Narita , , Japan

Ohgaki , , Japan

Okayama , , Japan

Osaka , , Japan

Sendai-shi , , Japan

Shibukawa , , Japan

Shibuya , , Japan

Tachikawa , , Japan

Toyohashi , , Japan

Busan , , Korea, Republic of

Gyeonggi-do , , Korea, Republic of

Hwasun , , Korea, Republic of

Incheon , , Korea, Republic of

Seongnam , , Korea, Republic of

Seoul , , Korea, Republic of

Skopje , , North Macedonia

Bialystok , , Poland

Bydgoszcz , , Poland

Chorzow , , Poland

Gdansk , , Poland

Legnica , , Poland

Lublin , , Poland

Opole , , Poland

Slupsk , , Poland

Warszawa Ul , , Poland

Warszawa , , Poland

Wroclaw , , Poland

Lisboa , , Portugal

Lisbon , , Portugal

Porto , , Portugal

Brasov , , Romania

Bucharest , , Romania

Iasi , , Romania

Arkhangelsk , , Russian Federation

Dzerzhinsk , , Russian Federation

Ekaterinbourg , , Russian Federation

Nizhny Novgorod , , Russian Federation

Ryazan , , Russian Federation

Saint-Petersburg , , Russian Federation

Saratov , , Russian Federation

Sochi , , Russian Federation

St Petersburg , , Russian Federation

Volgograd , , Russian Federation

Belgrade , , Serbia

Nis , , Serbia

Novi Sad , , Serbia

Sremska Kamenica , , Serbia

Zemun , , Serbia

Andalucía , , Spain

Badalona , , Spain

Barcelona , , Spain

Córdoba , , Spain

Girona , , Spain

La Laguna , , Spain

Madrid , , Spain

Maranon , , Spain

Murcia N/a , , Spain

Ourense , , Spain

Pamplona , , Spain

Salamanca , , Spain

Sevilla , , Spain

Toledo , , Spain

Valencia , , Spain

Zaragoza , , Spain

Altindag , , Turkey

Ankara , , Turkey

Aydin , , Turkey

Izmir , , Turkey

Kayseri , , Turkey

Samsun , , Turkey

Tekirdag , , Turkey

Cherkassy , , Ukraine

Dnepropetrovsk , , Ukraine

Ivano-Frankivsk , , Ukraine

Kharkov , , Ukraine

Khmelnitskiy , , Ukraine

Lviv , , Ukraine

Zaporizhzhia , , Ukraine

Birmingham , , United Kingdom

Cambridge , , United Kingdom

Colchester , , United Kingdom

Harlow , , United Kingdom

Leicester , , United Kingdom

London , , United Kingdom

Manchester , , United Kingdom

Woolwich , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

706

Study ID:

NCT02195479

Recruitment Status:

Active, not recruiting

Sponsor:


Janssen Research & Development, LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.